Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 07-Dec-23 8:21 PM View:  | Gall Matthew Chief Financial Officer | Iteos Therapeutics, Inc. (ITOS) | 05-Dec-23 | Grant | 41,000 | -- | -- | 211% 19.43K to 60.43K | |
| 07-Dec-23 8:22 PM View: | Call Matthew Chief Operating Officer | Iteos Therapeutics, Inc. (ITOS) | 05-Dec-23 | Grant | 44,000 | -- | -- | 47% 93.9K to 137.9K | |
| 07-Dec-23 8:22 PM View: | McGrath Yvonne Chief Scientific Officer | Iteos Therapeutics, Inc. (ITOS) | 05-Dec-23 | Grant | 31,000 | -- | -- | 100% 0 to 31.0K | |
| 07-Dec-23 8:20 PM View: | Detheux Michel Chief Executive Officer | Iteos Therapeutics, Inc. (ITOS) | 05-Dec-23 | Grant | 30,000 | -- | -- | 104% 28.9K to 58.9K | |
| 12-Oct-23 5:09 PM View: | Gall Matthew Chief Financial Officer | Iteos Therapeutics, Inc. (ITOS) | 12-Oct-23 | Private Purchase | 5,000 | $8.37 | $41,850.00 | 35% 14.43K to 19.43K | |
| 25-Aug-23 9:28 PM View: | Boxer Capital, LLC | Iteos Therapeutics, Inc. (ITOS) | 23-Aug-23 | Sale | 350,000 | $16.26 | $5,692,670.00 | (16%) 2.15M to 1.8M | |
| 29-Mar-23 8:00 PM View: | Call Matthew Chief Operating Officer | Iteos Therapeutics, Inc. (ITOS) | 28-Mar-23 | Option Exercise | 40,226 | $2.95 | $118,667.00 | 75% 53.67K to 93.9K | |
| 10-Jun-22 7:51 PM View: | Hallal David Director | Iteos Therapeutics, Inc. (ITOS) | 09-Jun-22 | Option Sale | 1,171 | $19.51 | $22,846.20 | (100%) 1.17K to 0 | |
| 10-Jun-22 7:51 PM View: | Hallal David Director | Iteos Therapeutics, Inc. (ITOS) | 09-Jun-22 | Option Exercise | 1,171 | $4.23 | $4,953.33 | 100% 0 to 1.17K | |
| 10-Jun-22 7:51 PM View: | Hallal David Director | Iteos Therapeutics, Inc. (ITOS) | 08-Jun-22 | Option Sale | 28,444 | $20.19 | $574,367.00 | (100%) 28.44K to 0 | |
| 10-Jun-22 7:51 PM View: | Hallal David Director | Iteos Therapeutics, Inc. (ITOS) | 08-Jun-22 | Option Exercise | 28,444 | $3.69 | $105,087.00 | 100% 0 to 28.44K | |
| 11-May-22 9:15 PM View: | Davis Aaron I. Director | Iteos Therapeutics, Inc. (ITOS) | 11-May-22 | Sale | 338,000 | $18.25 | $6,167,420.00 | (14%) 2.49M to 2.15M | |
| 11-May-22 9:15 PM View: | Davis Aaron I. Director | Iteos Therapeutics, Inc. (ITOS) | 10-May-22 | Sale | 100,000 | $25.16 | $2,515,970.00 | (4%) 2.59M to 2.49M | |
| 11-May-22 9:15 PM View: | Davis Aaron I. Director | Iteos Therapeutics, Inc. (ITOS) | 09-May-22 | Sale | 225,000 | $23.40 | $5,265,840.00 | (8%) 2.82M to 2.59M | |
| 02-May-22 9:15 PM View: | Davis Aaron I. Director | Iteos Therapeutics, Inc. (ITOS) | 02-May-22 | Sale | 100,000 | $27.49 | $2,748,730.00 | (3%) 2.92M to 2.82M | |
| 02-May-22 9:15 PM View: | Davis Aaron I. Director | Iteos Therapeutics, Inc. (ITOS) | 29-Apr-22 | Sale | 125,000 | $27.11 | $3,388,820.00 | (4%) 3.04M to 2.92M | |
| 02-May-22 9:15 PM View: | Davis Aaron I. Director | Iteos Therapeutics, Inc. (ITOS) | 28-Apr-22 | Sale | 150,000 | $27.40 | $4,110,320.00 | (5%) 3.19M to 3.04M | |
| 19-Apr-22 7:59 PM View: | Detheux Michel Chief Executive Officer | Iteos Therapeutics, Inc. (ITOS) | 18-Apr-22 | Option Exercise | 11,500 | $4.23 | $48,645.00 | 44% 26.26K to 37.76K | |
| 19-Apr-22 7:59 PM View: | Detheux Michel Chief Executive Officer | Iteos Therapeutics, Inc. (ITOS) | 18-Apr-22 | Option Sale | 11,500 | $31.87 | $366,530.00 | (30%) 37.76K to 26.26K | |
| 24-Mar-22 9:00 PM View: | Davis Aaron I. Director | Iteos Therapeutics, Inc. (ITOS) | 23-Mar-22 | Purchase | 20,000 | $32.85 | $656,980.00 | < 1% 3.17M to 3.19M | |
| 22-Mar-22 8:05 PM View: | Detheux Michel Chief Executive Officer | Iteos Therapeutics, Inc. (ITOS) | 22-Mar-22 | Sale (Planned) | 18,437 | $34.17 | $629,987.00 | (41%) 44.7K to 26.26K | |
| 24-Mar-22 9:00 PM View: | Davis Aaron I. Director | Iteos Therapeutics, Inc. (ITOS) | 22-Mar-22 | Private Purchase | 30,000 | $32.28 | $968,509.00 | < 1% 3.14M to 3.17M | |
| 18-Mar-22 9:00 PM View: | Boxer Capital, LLC 10% Owner | Iteos Therapeutics, Inc. (ITOS) | 17-Mar-22 | Sale | 575,201 | $35.25 | $20,275,800.00 | (15%) 3.72M to 3.14M | |
| 14-Mar-22 8:01 PM View: | Lager Joanne Jenkins Chief Medical Officer | Iteos Therapeutics, Inc. (ITOS) | 11-Mar-22 | Option Exercise | 3,500 | $4.30 | $15,050.00 | 100% 0 to 3.5K | |
| 14-Mar-22 7:59 PM View: | Detheux Michel Chief Executive Officer | Iteos Therapeutics, Inc. (ITOS) | 11-Mar-22 | Grant | 10,000 | -- | -- | 29% 34.7K to 44.7K | |
| 14-Mar-22 8:01 PM View: | Lager Joanne Jenkins Chief Medical Officer | Iteos Therapeutics, Inc. (ITOS) | 11-Mar-22 | Option Sale | 3,500 | $36.01 | $126,035.00 | (100%) 3.5K to 0 | |
| 02-Mar-22 7:59 PM View: | McGrath Yvonne Chief Scientific Officer | Iteos Therapeutics, Inc. (ITOS) | 01-Mar-22 | Option Exercise | 10,000 | $4.24 | $42,400.00 | 100% 0 to 10.0K | |
| 02-Mar-22 7:59 PM View: | McGrath Yvonne Chief Scientific Officer | Iteos Therapeutics, Inc. (ITOS) | 01-Mar-22 | Option Sale | 10,000 | $36.76 | $367,570.00 | (100%) 10.0K to 0 | |
| 24-Feb-22 8:00 PM View: | Detheux Michel Chief Executive Officer | Iteos Therapeutics, Inc. (ITOS) | 23-Feb-22 | Sale (Planned) | 14,500 | $34.34 | $497,905.00 | (29%) 49.2K to 34.7K | |
| 14-Feb-22 7:59 PM View: | Lager Joanne Jenkins Chief Medical Officer | Iteos Therapeutics, Inc. (ITOS) | 11-Feb-22 | Planned Option Sale | 3,500 | $35.85 | $125,459.00 | (100%) 3.5K to 0 | |
| 14-Feb-22 7:59 PM View: | Lager Joanne Jenkins Chief Medical Officer | Iteos Therapeutics, Inc. (ITOS) | 11-Feb-22 | Option Exercise | 3,500 | $4.30 | $15,050.00 | 100% 0 to 3.5K | |
| 26-Jan-22 7:53 PM View: | Detheux Michel Chief Executive Officer | Iteos Therapeutics, Inc. (ITOS) | 25-Jan-22 | Sale (Planned) | 14,500 | $35.68 | $517,378.00 | (23%) 63.7K to 49.2K | |
| 18-Jan-22 8:02 PM View: | Lager Joanne Jenkins Chief Medical Officer | Iteos Therapeutics, Inc. (ITOS) | 14-Jan-22 | Planned Option Sale | 3,500 | $39.32 | $137,614.00 | (100%) 3.5K to 0 | |
| 18-Jan-22 8:02 PM View: | Lager Joanne Jenkins Chief Medical Officer | Iteos Therapeutics, Inc. (ITOS) | 14-Jan-22 | Option Exercise | 3,500 | $4.30 | $15,050.00 | 100% 0 to 3.5K | |
| 06-Jan-22 4:12 PM View: | Mpm Bioventures 2014, L.P. 10% Owner | Iteos Therapeutics, Inc. (ITOS) | 05-Jan-22 | Market Sale | 18,135 | $42.03 | $762,214.00 | (< 1%) 13.84M to 13.82M | < 1% |
| 06-Jan-22 4:13 PM View: | Mpm Bioventures 2018, L.P. 10% Owner | Iteos Therapeutics, Inc. (ITOS) | 05-Jan-22 | Market Sale Duplicate | 18,135 | $42.03 | $762,214.00 | (< 1%) 13.84M to 13.82M | < 1% |
| 06-Jan-22 4:12 PM View: | Gadicke Ansbert 10% Owner | Iteos Therapeutics, Inc. (ITOS) | 05-Jan-22 | Market Sale | 30,347 | $42.03 | $1,275,480.00 | (< 1%) 22.67M to 22.64M | < 1% |
| 06-Jan-22 4:12 PM View: | Mpm Bioventures 2014, L.P. 10% Owner | Iteos Therapeutics, Inc. (ITOS) | 04-Jan-22 | Market Sale | 128,550 | $42.66 | $5,483,840.00 | (< 1%) 13.97M to 13.84M | 2% |
| 06-Jan-22 4:13 PM View: | Mpm Bioventures 2018, L.P. 10% Owner | Iteos Therapeutics, Inc. (ITOS) | 04-Jan-22 | Market Sale Duplicate | 128,550 | $42.66 | $5,483,840.00 | (< 1%) 13.97M to 13.84M | 2% |
| 06-Jan-22 4:12 PM View: | Gadicke Ansbert 10% Owner | Iteos Therapeutics, Inc. (ITOS) | 04-Jan-22 | Market Sale | 215,122 | $42.66 | $9,176,850.00 | (< 1%) 22.88M to 22.67M | 2% |
| 05-Jan-22 9:20 PM View: | Boxer Capital, LLC Director 10% Owner | Iteos Therapeutics, Inc. (ITOS) | 04-Jan-22 | Market Sale | 184,677 | $42.77 | $7,898,260.00 | (5%) 3.9M to 3.72M | 2% |
| 04-Jan-22 10:00 PM View: | Lager Joanne Jenkins Chief Medical Officer | Iteos Therapeutics, Inc. (ITOS) | 03-Jan-22 | Option Exercise | 7,000 | $4.30 | $30,100.00 | 100% 0 to 7.0K | |
| 05-Jan-22 9:20 PM View: | Boxer Capital, LLC Director 10% Owner | Iteos Therapeutics, Inc. (ITOS) | 03-Jan-22 | Market Sale | 515,323 | $47.89 | $24,677,400.00 | (12%) 4.42M to 3.9M | 12% |
| 04-Jan-22 10:00 PM View: | Biniszkiewicz Detlev Director | Iteos Therapeutics, Inc. (ITOS) | 03-Jan-22 | Option Exercise | 3,500 | $19.00 | $66,500.00 | 100% 0 to 3.5K | |
| 04-Jan-22 10:00 PM View: | Lager Joanne Jenkins Chief Medical Officer | Iteos Therapeutics, Inc. (ITOS) | 03-Jan-22 | Market Option Sale (Planned) | 7,000 | $51.90 | $363,300.00 | (100%) 7.0K to 0 | |
| 04-Jan-22 10:00 PM View: | Biniszkiewicz Detlev Director | Iteos Therapeutics, Inc. (ITOS) | 03-Jan-22 | Market Option Sale (Planned) | 3,500 | $51.90 | $181,650.00 | (100%) 3.5K to 0 | |
| 28-Dec-21 8:58 PM View: | Gall Matthew Chief Financial Officer | Iteos Therapeutics, Inc. (ITOS) | 27-Dec-21 | Market Sale | 5,000 | $46.45 | $232,250.00 | (26%) 19.43K to 14.43K | (< 1%) |
| 22-Dec-21 8:01 PM View: | Detheux Michel Chief Executive Officer | Iteos Therapeutics, Inc. (ITOS) | 22-Dec-21 | Market Sale (Planned) | 14,500 | $45.03 | $652,996.00 | (19%) 78.2K to 63.7K | |
| 22-Dec-21 8:01 PM View: | Detheux Michel Chief Executive Officer | Iteos Therapeutics, Inc. (ITOS) | 22-Dec-21 | Option Exercise | 1,663 | $4.30 | $7,150.90 | 2% 78.2K to 79.86K | |
| 22-Dec-21 8:01 PM View: | Detheux Michel Chief Executive Officer | Iteos Therapeutics, Inc. (ITOS) | 22-Dec-21 | Market Option Sale (Planned) | 1,663 | $45.03 | $74,891.90 | (2%) 79.86K to 78.2K |
